Intellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines Conference. Trova l’ultima quotazione dei titoli di Intellia Therapeutics, Inc. (NTLA), cronologia, notizie e altre informazioni essenziali per scambiare titoli e investire al meglio. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s ability to advance and expand the CRISPR/Cas9 technology to develop into human therapeutic products, as well as our CRISPR/Cas9 intellectual property portfolio; achieve stable or effective genome editing; the timing and potential achievement of milestones to advance our pipeline and grow as a company; and the anticipated contribution of the members of our board of directors and our executives, or our scientific founders, to our operations and progress.Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Dr. Doudna also is a senior investigator at the Gladstone Institutes and an adjunct professor of Cellular and Molecular Pharmacology at UC San Francisco. Rodolphe Barrangou, Eric Sontheimer, Luciano Marrafini and Derrick Rossi, who have each made, and continue to make, tremendous contributions to the genomics field.”About Jennifer Doudna Dr. Doudna is a faculty member of the Molecular and Cell Biology and Chemistry department at UC Berkeley, where she is the Li Ka Shing Chancellor’s Professor of Biomedical Science, as well as a Howard Hughes Medical Institute investigator, and a faculty scientist at the Lawrence Berkeley National Laboratory. Crowley brings relevant experience to Intellia’s board, having started preeminent biotech companies with successful programs that transitioned from preclinical to clinical development, and importantly, a commercialized medicine available for patients. Crowley became a principal advocate for the treatment of the severe and often fatal neuromuscular disorder, Pompe disease. The clock just started on the biggest financial event in 20 years. Mr. Karsen served as chairman of Intellia’s Board of Directors from April 2016 through February 2020, including the company’s 2016 initial public offering. “Together, with our experienced and diverse senior leadership team, Intellia’s board of directors will help us achieve our goals and deliver value to our patients and our shareholders.”Mr. Doudna and Charpentier have been awarded the Lurie Prize in the Biomedical Sciences, the Dr. Paul Janssen Award for Biomedical Research, the Dr. H. P. Heineken Prize for Biochemistry and Biophysics, and the LUI Che Woo Prize for Welfare Betterment, among other recognitions.“We congratulate Dr. Doudna and Dr. Charpentier on winning the 2020 Nobel Prize in Chemistry for their revolutionary invention of CRISPR/Cas9,” said Intellia President and Chief Executive Officer John Leonard, M.D. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.Intellia Contacts:Media: Jennifer Mound Smoter Senior Vice President                                                              External Affairs & Communications                                        +1 857-706-1071                                                                            jenn.smoter@intelliatx.com                                         Lynnea Olivarez Director External Affairs & Communications +1 956-330-1917 lynnea.olivarez@intelliatx.comInvestors: Lina Li Associate Director Investor Relations +1 857-706-1612 lina.li@intelliatx.com, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real Time Price. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s ability to advance and expand the CRISPR/Cas9 technology to develop into human therapeutic products, as well as our CRISPR/Cas9 intellectual property portfolio; achieve stable or effective genome editing; the timing and potential achievement of milestones to advance our pipeline and grow as a company; and the anticipated contribution of the members of our board of directors and our executives, or our scientific founders, to our operations and progress.Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.